“Pneumococcal Infections Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Pneumococcal Infections Market.
The Pneumococcal Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Pneumococcal Infections Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Pneumococcal Infections and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pneumococcal Infections market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Pneumococcal infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intranasal
Intrathecal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
Antisense oligonucleotide
Gene therapy
Hormones
Neuropeptides
Oligonucleotides
Small Molecule
Triglyceride
Learn How the Ongoing Clinical & Commercial Activities will Affect the Pneumococcal Infections Therapeutic Segment @
https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight
Pneumococcal Infections Therapeutics Landscape
There are approx. 15+ key companies developing therapies for Pneumococcal infections. Currently, Affinivax is leading the therapeutics market with its Pneumococcal infections drug candidates in the most advanced stage of clinical development.
The Leading Players in the Pneumococcal Infections Therapeutics Market Include:
Affinivax
Astellas Pharma
Beijing Zhifei Lvzhu Biopharmaceutical
CanSino Biologics Inc.
EuBiologics
Gangagen
GlaxoSmithKline
ImmunoBiology
LG Life Sciences
Merck Sharp & Dohme
Panacea Biotech
Pfizer
SK Chemicals Co., Ltd.
SutroVax
Vaxcyte
And Many Others
Pneumococcal Infections Emerging and Marketed Drugs Covered in the Report Include:
ASP3772: Affinivax
ASP3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The results from the Phase II clinical trial demonstrated that ASP3772 was well tolerated.
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older.
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Pneumococcal Infections Current Treatment Patterns
4. Pneumococcal Infections – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Pneumococcal Infections Late Stage Products (Phase-III)
7. Pneumococcal Infections Mid-Stage Products (Phase-II)
8. Pneumococcal Infections Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pneumococcal Infections Discontinued Products
13. Pneumococcal Infections Product Profiles
14. Key Companies in the Pneumococcal Infections Market
15. Key Products in the Pneumococcal Infections Therapeutics Segment
16. Dormant and Discontinued Products
17. Pneumococcal Infections Unmet Needs
18. Pneumococcal Infections Future Perspectives
19. Pneumococcal Infections Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/